Acute critical illness in patients without previous renal disease increases their risk of kidney complications and death. According to Dr.
Tag: Renal disease
Jynarque for treating kidney disease
FDA approves Jynarque (tolvaptan) to slow kidney function decline in rapidly progressing autosomal dominant polycystic kidney disease ADPKD. ADPKD is
